Technology

Our disruptive technology delivers a fast acting powder-form drug formulation which has been developed by using our patent-pending methodology, and “trade secret” process. Our technology helps drugs and supplements absorb quickly under the tongue.

Aspire’s sublingual dose form avoids some harmful side effects of various drug therapies while maintaining or enhancing benefits. These results come from a new mechanism of action (absorption pathway) which allows for rapid sublingual absorption in the mouth.

The speed of absorption and level of absorption due to our new technology into the blood stream is significant. Aspire’s sublingual dose form avoids some harmful side effects of various drug therapies while maintaining or enhancing benefits. It avoids direct damage to mucus secreting Goblet cells lining the GI track and avoids bioavailability reduction by first pass hepatic metabolism.

Aspire formula

Fast Acting
Medication using our patented delivery technology gets there faster

Perfects Dosage Management
Drugs do not pass through the liver and are not
metabolized

Bypasses the Digestive Tract
Eliminates adverse reactions in the gastrointestinal tract

Easy to Use
No more difficulty with swallowing pills or capsules

Our technology can be applied to any number of proven drugs and supplements. The list below are just a few examples, but there are undoubtedly many more.

- Analgesics – global analgesics market (including Opioids) valued approximately $77.0 billion in 2021 and is projected to grow at a 5% CAGR and reach to roughly $103.0 billion by 2028

- Erectile Dysfunction (ED) – global ED market valued approximately $3.6 billion in 2021 and is projected to grow at a 6.9% CAGR and reach to roughly $5.9 billion by 2028

- Caffeine Pre-Workout – global pre-workout market value at approximately $19.58 billion in 2024 and growing.

Aspire Biopharma, Inc. has developed a disruptive technology which addresses emergencies, drug efficacy, dosage management, and response time.

Aspire’s launch product, sublingual aspirin, will address cardiology and stroke emergencies, acute pain management and anti-inflammatory needs.

Benefits of “rapid absorption” aspirin are: to stop heart attack and stroke; allow high-dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.

The sublingual aspirin product is also targeted to be a safe and effective Opioid alternative.

Aspire’s sublingual aspirin product completed clinical trials in July 2025, with great results. We hope to file our 505(b)(2) application with the FDA in 2025 seeking fast-track approval.